Implementation of Injectable Cabotegravir/Rilpivirine for Treatment of Human Immunodeficiency Virus in Patients With Substance Use Disorders at a Syringe Exchange Clinic

Amanda Perez; Shane Nieves; Jessica Meisner

doi:10.1093/ofid/ofae640

Implementation of Injectable Cabotegravir/Rilpivirine for Treatment of Human Immunodeficiency Virus in Patients With Substance Use Disorders at a Syringe Exchange Clinic

Open Forum Infect Dis. 2024 Oct 23;11(11):ofae640. doi: 10.1093/ofid/ofae640. eCollection 2024 Nov.

Authors

Amanda Perez¹, Shane Nieves², Jessica Meisner^{2

3}

Affiliations

¹ Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
² Prevention Point Philadelphia, Philadelphia, Pennsylvania, USA.
³ Division of Infectious Diseases, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Abstract

Cabotegravir + rilpivirine (CAB + RPV-LA) is a long-acting antiretroviral therapy (ART) that can be utilized for people with human immunodeficiency virus (HIV) who face barriers to daily ART. Here, we describe the implementation of a program that provides low-barrier access to CAB + RPV-LA for people with HIV and opioid use disorder at a syringe exchange.

Keywords: cabotegravir; human immunodeficiency virus; opioid use disorder; rilpivirine; syringe exchange.